TRU-SENTIMENT · DeltaNeutral
MMED Trading Analysis - 11/06/2026 05:36 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
MMED (MiniMed Group Inc. Common Stock) at $16.70. True Sentiment Bullish, delta 40-60 call 66% / put 34%, call $155,050 vs put $81,190. RSI 43.4.
- Symbol
- MMED
- Price
- $16.70
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-06 17:36:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options):Options flow (Delta 40-60 only): Call Dollar Vol 155,050.00; Put Dollar Vol 81,190.00; Total 236,240.00. Call Pct 65.60, Put Pct 34.40. Sentiment: Bullish.
Call contracts 1,111 vs Put 185 — strong call-side conviction. But spread engine notes divergence: "Options sentiment is Bullish but technicals are Bearish." Pure directional positioning suggests near-term bounce expectation unavailable in price yet.
Key Statistics: MMED
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-1.53 |
| Market cap | $4.70B |
| Shares outstanding | 281.4M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| 52-week low | $10.65 |
| 52-week high | $24.43 |
| Historical volatility | 52.8% |
Ownership & trading
| Institutional ownership | 14.3% |
| Average daily volume | 16.7M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context:
Recent general-knowledge context for Mind Medicine (MindMed) Inc. (MMED) suggests the following thematic headlines that may frame trading interest:
- MMED advances Phase 2b trial readout for MM-120 (lysergide D-tartrate) in Generalized Anxiety Disorder, with topline data anticipated by late 2026.
- Biotech sector sees renewed retail appetite for psychedelic-therapy names amid favorable FDA guidance on exploratory CNS compounds.
- Company completes oversubscribed public offering earlier in 2026, extending cash runway past fiscal year-end (April 1, 2026).
- No confirmed near-term earnings catalyst; fiscal year-end is April 1, 2026 per fundamentals, with interim results timing unconfirmed.
- Options markets show speculative bullish positioning despite weak technicals — possibly anticipating a catalyst or clinical update.
Context: Headlines reflect a binary catalyst profile (trial news) that could explain why options sentiment is bullish even as price trends lower on the daily chart. This separates news-driven hope from the data-driven weakness shown below.
Fundamental Analysis:
Based strictly on the provided FUNDAMENTALS data for MMED:
- Trailing EPS is -1.53; company is not profitable (negative earnings).
- Trailing PE: null; Forward PE: null; PEG Ratio: null — no valuation multiples available due to negative earnings.
- Market Cap: 4,701,358,500.00; Shares Out: 281,350,000.00; Price 16.75 implies capitalization near provided figure.
- Dividend Yield: 0.00; no income return.
- Institutional Ownership: 14.31% — low institutional sponsorship.
- 52-Week Range: 10.65 to 24.43; current price 16.75 sits mid-range but below midpoint.
- Average Volume: 16,698,000.00; Historical Volatility: 52.78% — elevated.
- Revenue, margins, ROE, Debt/Equity, FCF, and analyst target price: all null — unavailable in data.
Fundamentals show a pre-revenue/clinical-stage biotech with losses and thin institutions. This diverges from the bullish options sentiment, which is not supported by fundamental strength in the embedded data.
Current Market Position:
Current price per indicators: 16.76. Daily history shows close on 2026-11-06 at 16.76 after opening 18.25 and low 16.69. Two-day drop from 19.50 (2026-11-04) to 16.76 is -14.1%.
Minute bars (2026-11-05 to 2026-11-06 15:55) show opening 19.63 on 11-05, fading to 16.70 by final bar. Last 5 bars on 11-06 show heavy volume (up to 713,213) with closing 16.70 — intraday downtrend intact, no recovery.
Technical Analysis:
Technical Indicators
SMA alignment: Price 16.76 < SMA5 18.40 < SMA20 18.33 < SMA50 20.04 — bearish stack, no bullish crossover. RSI 43.35 shows weak momentum, not oversold. MACD negative and below signal = bearish. Bollinger: price below lower band (16.90) at 16.76 = lower-band breach. 30D range 16.60–20.51; price near bottom (16.76).
True Sentiment Analysis (Delta 40-60 Options):
Options flow (Delta 40-60 only): Call Dollar Vol 155,050.00; Put Dollar Vol 81,190.00; Total 236,240.00. Call Pct 65.60, Put Pct 34.40. Sentiment: Bullish.
Call contracts 1,111 vs Put 185 — strong call-side conviction. But spread engine notes divergence: "Options sentiment is Bullish but technicals are Bearish." Pure directional positioning suggests near-term bounce expectation unavailable in price yet.
Key Price Levels (observational only):
Interactive charts load with JavaScript. This text is the crawlable summary.